Lin2013 -025 Jianfeng Group Related Transactions
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临 2013-025
浙江尖峰集团股份有限公司 关于收购尖峰水泥股权的关联交易公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、关联交易概述 浙江尖峰集团股份有限公司(以下简称“公司”、“本公司”或者“尖峰集
团”)拟以 871 万元的价格收购金华峰联投资有限公司(以下简称“金华峰联”) 持有的浙江尖峰水泥有限公司(以下简称“尖峰水泥”)1.34%的股权。2013 年 8
月 14 日,公司与金华峰联在金华签署了股权转让协议。 因金华峰联是本公司董事控制的企业,根据《股票上市规则》的规定本次交
易构成了上市公司的关联交易。本次关联交易金额为 871 万元,占本公司 2012 年末经审计净资产的 0.57%;对照《上市公司重大资产重组管理办法》的规定, 本次关联交易不构成重大资产重组。至本次关联交易为止,过去 12 个月内上市
公司与同一关联人或与不同关联人之间交易类别相关的关联交易未达到 3000 万 元以上,也未达到占公司最近一期经审计净资产绝对值 5%以上。
本关联交易需经董事会审议,但不需提交股东大会审议。 二、关联方介绍
(一)关联方关系介绍 公司董事杜自弘是金华峰联投资有限公司的控股股东,公司董事蒋晓萌、虞
建红是金华峰联的股东。根据《上海证券交易所股票上市规则》的规定,本次股 权转让构成关联交易,三位关联董事在董事会审议本议案时回避了表决。
(二)关联人基本情况 1、名称:金华峰联投资有限公司
2、企业性质:有限责任公司
3、注册地:金华市八一南街金发广场
4、主要办公地点:金华市八一南街金发广场
5、法定代表人:雷根华
6、注册资本:2000 万元
7、主营业务:实业投资、投资咨询、投资服务
8、关联人最近一年的主要财务指标
截止 2012 年 12 月 31 日,金华峰联的资产总额 5253.86 万元,净资产 3375.36 万元;2012 年的净利润为-168.35 万元。
三、关联交易标的基本情况
(一)交易标的
(1)企业名称:浙江尖峰水泥有限公司
(2)成立时间:1999 年 4 月 13 日
(3)注册地址:金华市婺江东路 88 号
(4)注册资本:17862 万元
(5)企业性质:有限责任公司
(6)法定代表人:徐志毅
(7)主营业务:水泥销售;建筑材料、普通机械、纸制品、装潢材料销售。 石灰石采选销售(仅限办理分支机构)。
(8)主要股东持股比例:本公司持有 93.91%;金华市通济国有投资有限公 司持有 4.75%;金华峰联持有 1.34%。
(9)浙江尖峰水泥有限公司最近一年一期的主要财务数据
截止 2012 年 12 月 31 日尖峰水泥的总资产 92662.15 万元,归属于母公司的
净资产 45204.13 万元;2012 年实现营业收入 57201.99 万元,归属于母公司净
利润 5544.77 万元,扣除非经常性损益后的净利润 5469.09 万元(经天健会计 师事务所审计)。
2013 年 6 月 30 日尖峰水泥的总资产 87760.77 万元,归属于母公司的净资产
48172.44 万元;2013 年上半年实现营业收入 26947.79 万元,归属于母公司的净
利润 2968.31 万元,扣除非经常性损益后的净利润 2838.34 万元(未经审计)。
(10)标的股权的产权清晰,不存在抵押、质押及其他任何限制转让的情况, 不涉及诉讼、仲裁事项或查封、冻结等司法措施以及妨碍权属转移的其他情况。
(二)关联交易价格的确定
1、本次股权转让,聘请了具有从事证券、期货业务资格的坤元资产评估有 限公司进行了资产评估。评估基准日为 2012 年 12 月 31 日。对于经营性资产, 采用市场法进行评估;对非经营性资产,分别采用成本法和市场法进行评估。标 的股权的评估值为 871 万元。截止 2012 年 12 月 31 日尖峰水泥的账面净资产为
45204.13 万元,对应标的股权的账面值为 605.74 万元。
2、本次股权转让以坤元资产评估有限公司出具的《资产评估报告》确定的 评估值为转让价。
四、关联交易的主要内容和履约安排
(一)交易双方 1、甲方:金华峰联
2、乙方:尖峰集团
(二)转让价格 乙方收购标的股权的价格为人民币 871 万元。
(三)支付方式和期限 本次股权转让款分两期支付。
首期转让款,在协议生效 10 天之内,乙方向甲方以现金支付股权转让价款 的 50%,计:人民币 435.5 万元。大写:肆佰叁拾伍万伍仟元整。
第二期转让款,在完成股权的工商变更登记手续后 15 天内再支付剩余 50%
股权转让款,计人民币 435.5 万元,大写:肆佰叁拾伍万伍仟元整。
(四)过户时间安排 相关工商变更登记手续由乙方负责办理,甲方配合。在乙方支付首期股权转
让款后,办理相关工商变更登记手续。 五、本次关联交易的目的及对公司的影响
本次收购的股权是水泥行业的资产,符合公司的发展战略。完成此次收购后, 将增加公司对尖峰水泥的持股比例,有利于进一步优化公司的资产布局。
六、该关联交易应当履行的审议程序
2013 年 8 月 14 日,公司召开了第八届董事会第十二次会议,关联董事蒋晓 萌先生、杜自弘先生、虞建红先生回避了该议案的表决。经审议与表决,董事会 以 6 票同意、0 票反对、0 票弃权审议通过了该议案。
公司三名独立董事对本次关联交易进行了事前审核,并出具了事前认可声
明。三名独立董事表决同意本次关联交易,并发表了独立意见,认为:本次关联 交易价格公允,不存在损害公司及股东利益的情况,符合公司的发展战略和经营 目标,有利于进一步优化公司的资产布局。董事会的审议和表决程序合法有效, 符合《公司章程》及其他法律、法规和规范性文件的要求。
七、上网公告附件
(一)经独立董事事前认可的声明
(二)经独立董事签字确认的独立董事意见
(三)评估报告 特此公告
浙江尖峰集团股份有限公司
董事会 二〇一三年八月十六日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11